Kala Pharmaceuticals submits NDA to FDA for KPI-121 0.25% for dry eye disease
Kala Pharmaceuticals announced it has submitted a New Drug Application to the FDA for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease. October 16, 2018